

VIA HAND DELIVERY JANUARY 25, 2001

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of: **MOORE et al.**

Application Number: 09/084,491



Filed: May 27, 1998

Title: **Tissue Plasminogen  
Activator-Like Protease**

Group Art Unit: 1652

Examiner: Slobodyansky, E.

Attorney Docket No.: PF378



#21  
M.G.  
1/21/01

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT PURSUANT TO 37 CFR 1.97(c)**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorneys and/or Agents for Applicants hereby direct the Examiner's attention to references BS-BV listed on the attached Form PTO/SB/08. A copy of references BS, BU, and BV is enclosed. Because reference BT is over 5,000 pages in length, a partial copy of the reference omitting pages of the sequence listing and tables that Applicants do not believe to be relevant is enclosed; the complete reference will be provided at the Examiner's request. Within reference BT, the Examiner is directed particularly to SEQ ID NOS:6001-02 at pages 385 (in Table 1) and 5178-80. The relevance of reference BU can be found at pages 79 (SEQ ID NO:10) and 131-132 (SEQ ID NOS:89-91).

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file

history of the application, and consider the information contained therein during the prosecution of this application.


Identification of the listed references is not to be construed an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), although this Supplemental Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits, the Patent and Trademark Office will consider the Supplemental Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p).

The Patent Office is authorized to charge the required fee of \$180.00, and any other fee deemed necessary, to Human Genome Sciences, Inc., Deposit Account No. 08-3425. A copy of this sheet is enclosed.

Respectfully submitted,

Dated: January 25, 2001

  
Mark J. Hyman (Reg. No. 46,789)  
Attorney for Applicants

**Human Genome Sciences, Inc.**  
9410 Key West Avenue  
Rockville, MD 20850  
Telephone: (240) 314-1224

Enclosures